CAR-T Cell Therapy Cost and Success Rates: A Patient's Guide

The Promise and the Price Tag

CAR-T cell therapy represents one of the most significant advances in cancer treatment in the past two decades. By genetically reprogramming a patient's own immune cells to hunt and destroy cancer, it has produced durable remissions in patients who had exhausted every other option. But alongside the remarkable clinical outcomes comes a stark reality: CAR-T is among the most expensive medical treatments ever developed.

For patients and families navigating a cancer diagnosis, understanding both the potential benefits and the financial burden of CAR-T therapy is critical. This guide breaks down the costs of every FDA-approved CAR-T product, the success rates across different cancer types, the side effects to expect, and the practical realities of insurance coverage and total out-of-pocket exposure.

FDA-Approved CAR-T Therapies: Pricing and Indications

As of early 2026, six CAR-T cell therapies have received FDA approval. Each targets a different set of cancers and carries a different list price for the drug itself. These prices do not include hospitalization, supportive care, or other associated costs -- those are discussed in a later section.

Kymriah (Tisagenlecleucel) -- Novartis

List price: $373,000 (for ALL); $475,000 (for DLBCL)
Approved indications: Relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in patients up to age 25; relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults after two or more lines of systemic therapy; relapsed or refractory follicular lymphoma (FL) after two or more lines of therapy
Target antigen: CD19
First approved: 2017 (the first CAR-T product to receive FDA approval)

Kymriah holds a unique place in history as the therapy that opened the door for personalized cell-based cancer treatments. Novartis initially offered an outcomes-based pricing model for pediatric ALL, where the company would refund the cost if a patient did not respond within the first month. That program has since been modified but signaled early acknowledgment that the price demands justification through results.

Yescarta (Axicabtagene Ciloleucel) -- Kite Pharma / Gilead

List price: $373,000
Approved indications: Relapsed or refractory large B-cell lymphoma (including DLBCL) after two or more lines of systemic therapy; relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy (expanded indication approved 2022); relapsed or refractory follicular lymphoma after two or more lines of therapy
Target antigen: CD19
First approved: 2017

Yescarta was the second CAR-T to reach the market and quickly became the most widely used product for large B-cell lymphoma. Its expanded approval as a second-line therapy -- meaning patients no longer need to fail two prior treatments before qualifying -- marked a significant shift in how aggressively CAR-T can be deployed.

Tecartus (Brexucabtagene Autoleucel) -- Kite Pharma / Gilead

List price: $373,000
Approved indications: Relapsed or refractory mantle cell lymphoma (MCL) in adults; relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in adults
Target antigen: CD19
First approved: 2020

Tecartus filled an important gap by providing a CAR-T option for mantle cell lymphoma, a relatively rare and aggressive B-cell cancer that had limited treatment options. Its manufacturing process includes a T-cell enrichment step that removes circulating tumor cells, which is particularly important in MCL where malignant cells can contaminate the collected blood product.

Breyanzi (Lisocabtagene Maraleucel) -- Bristol Myers Squibb

List price: $410,300
Approved indications: Relapsed or refractory large B-cell lymphoma (including DLBCL) after two or more lines of systemic therapy; relapsed or refractory large B-cell lymphoma after first-line therapy (expanded 2024); relapsed or refractory follicular lymphoma and marginal zone lymphoma after two or more lines of therapy; relapsed or refractory mantle cell lymphoma; relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Target antigen: CD19
First approved: 2021

Breyanzi distinguishes itself through a defined-composition manufacturing process that delivers a precise ratio of CD4+ and CD8+ CAR-T cells. It has been associated with somewhat lower rates of severe cytokine release syndrome compared to some other products, which may reduce hospitalization costs in practice. Its recent CLL/SLL indication represents the broadest label expansion of any CD19-directed CAR-T to date.

Abecma (Idecabtagene Vicleucel) -- Bristol Myers Squibb / 2seventy bio

List price: $419,500
Approved indications: Relapsed or refractory multiple myeloma in adults after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
Target antigen: BCMA (B-cell maturation antigen)
First approved: 2021

Abecma was the first CAR-T therapy approved for multiple myeloma, a blood cancer that until recently had no cell therapy options. Its approval was based on the KarMMa trial, which demonstrated meaningful response rates in a population with extremely limited alternatives. However, the requirement for four prior lines of therapy means patients must be heavily pretreated before qualifying.

Carvykti (Ciltacabtagene Autoleucel) -- Janssen / Legend Biotech

List price: $465,000
Approved indications: Relapsed or refractory multiple myeloma in adults after one or more prior lines of therapy (expanded from original four-line requirement in 2024), including a proteasome inhibitor and an immunomodulatory agent
Target antigen: BCMA
First approved: 2022

Carvykti has shown the highest response rates among the myeloma-directed CAR-T products. The CARTITUDE-4 trial, which supported its expanded indication as an earlier-line therapy, demonstrated a 73% reduction in the risk of disease progression or death compared to standard treatment. This earlier-line approval is expected to substantially increase the number of myeloma patients eligible for CAR-T.

Success Rates by Cancer Type

The word "success" in oncology requires careful definition. Clinicians typically measure outcomes in terms of overall response rate (ORR), complete remission rate (CR), duration of response, progression-free survival (PFS), and overall survival (OS). For patients, the most meaningful number is often the complete remission rate -- the percentage of patients whose cancer becomes undetectable -- and how long that remission lasts.

B-Cell Acute Lymphoblastic Leukemia (ALL)

CAR-T therapy has produced its most dramatic results in ALL, particularly in children and young adults.

Complete remission rate: 70-90%
Long-term durability: Approximately 50-60% of patients who achieve CR remain in remission at two years. Some patients from the earliest Kymriah trials remain disease-free more than eight years later.
Key trials: The ELIANA trial (Kymriah) reported an 82% overall remission rate in pediatric and young adult patients. The ZUMA-3 trial (Tecartus in adult ALL) showed a 71% CR rate.

These numbers are remarkable in context. The patients enrolled in these trials had cancer that had relapsed after standard chemotherapy, and many had relapsed after bone marrow transplants. Before CAR-T, the expected survival for these patients was often measured in months.

However, relapse remains a significant challenge. Approximately 30-50% of patients who initially achieve CR will eventually relapse, often because the leukemia cells lose the CD19 surface marker that the CAR-T cells are designed to target -- a phenomenon called antigen escape.

Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL is the most common type of non-Hodgkin lymphoma and has been the primary battleground for CAR-T development.

Complete remission rate: 40-54%
Long-term durability: Among patients who achieve CR, roughly 60-70% remain in remission at three years. Outcomes from the ZUMA-1 trial (Yescarta) show that about 40% of all treated patients are alive and progression-free at five years.
Key trials: ZUMA-1 (Yescarta) reported a 54% CR rate; JULIET (Kymriah) reported a 40% CR rate; TRANSFORM (Breyanzi as second-line) showed a 46% CR rate with superior event-free survival compared to standard-of-care salvage chemotherapy plus transplant.

The move toward using CAR-T as a second-line treatment -- rather than reserving it for patients who have failed three or more regimens -- has been one of the most important developments in the field. Three randomized trials (ZUMA-7 for Yescarta, TRANSFORM for Breyanzi, and BELINDA for Kymriah) compared CAR-T to autologous stem cell transplant as second-line therapy. Two of the three showed significant benefit for CAR-T, leading to expanded approvals.

Follicular Lymphoma (FL)

Follicular lymphoma is a slower-growing cancer, but it remains incurable with conventional therapy and tends to relapse repeatedly over years.

Complete remission rate: 60-70%
Long-term durability: Follow-up data are still maturing, but early results suggest durable remissions in a substantial proportion of patients.
Key trials: ZUMA-5 (Yescarta) reported a 79% CR rate in follicular lymphoma, and ELARA (Kymriah) showed a 69% CR rate.

The high response rates in FL have been encouraging, though the indolent nature of the disease makes long-term follow-up critical. Some researchers question whether the benefits justify the cost and toxicity in a cancer that, while not curable, can often be managed for years with less aggressive treatments.

Multiple Myeloma (MM)

Multiple myeloma was the last major blood cancer to gain a CAR-T option, and the results have been mixed but increasingly promising.

Complete remission rate: 30-40% (Abecma); 55-70% (Carvykti)
Long-term durability: Median progression-free survival is approximately 8-12 months with Abecma and 24+ months with Carvykti. Complete responses tend to be more durable, with some patients maintaining remission beyond three years.
Key trials: KarMMa (Abecma) showed a 33% CR rate; CARTITUDE-1 (Carvykti) showed a 67% stringent complete response rate with a median PFS of nearly three years in the most recent updates.

Carvykti has emerged as the stronger performer in myeloma, and its expansion to earlier lines of therapy represents a major shift. However, myeloma remains notoriously difficult to cure permanently, and most patients will eventually relapse even after CAR-T.

Mantle Cell Lymphoma (MCL)

Complete remission rate: 60-70%
Key trials: ZUMA-2 (Tecartus) reported a 67% CR rate in heavily pretreated MCL patients.

MCL tends to be aggressive, and the high response rates with Tecartus have been a welcome development for patients who previously had few options after first-line therapy failure.

Side Effects and Risks

CAR-T therapy is not chemotherapy, but it is far from side-effect-free. The engineered T cells trigger powerful immune reactions that can be life-threatening if not managed by experienced medical teams.

Cytokine Release Syndrome (CRS)

CRS is the most common serious side effect, occurring in 50-90% of patients depending on the product and cancer type. When CAR-T cells engage their targets and begin killing cancer cells, they release large quantities of cytokines -- inflammatory signaling molecules. In mild cases, CRS causes fever, fatigue, and muscle aches. In severe cases (Grade 3-4), it can cause dangerously low blood pressure, respiratory distress, organ dysfunction, and in rare cases, death.

CRS typically begins within the first one to 14 days after infusion and is managed with tocilizumab (an IL-6 receptor blocker) and corticosteroids. The vast majority of CRS cases resolve with treatment, but patients must remain hospitalized or near the treatment center for close monitoring during the risk window.

Severe CRS (Grade 3 or higher) occurs in roughly 10-25% of patients, though rates vary significantly by product. Breyanzi has been associated with lower rates of severe CRS compared to Yescarta, for example.

Neurotoxicity (ICANS)

Immune effector cell-associated neurotoxicity syndrome (ICANS) is the second most common serious adverse event, affecting 20-65% of patients. Symptoms range from mild confusion, difficulty finding words, and tremor to severe cases involving seizures, cerebral edema, and loss of consciousness.

ICANS typically occurs after or overlapping with CRS and usually resolves within days to weeks. It is managed with corticosteroids and supportive care. Severe ICANS (Grade 3 or higher) occurs in approximately 10-30% of patients.

The mechanism of ICANS is not fully understood, but it appears related to cytokine-mediated disruption of the blood-brain barrier. Patients with high tumor burden, pre-existing neurological conditions, or severe CRS are at higher risk.

B-Cell Aplasia and Hypogammaglobulinemia

Because all currently approved CAR-T therapies target proteins found on normal B cells (CD19 or BCMA), they destroy healthy B cells along with cancerous ones. This leads to B-cell aplasia -- a depletion of the body's B-cell population -- and consequent hypogammaglobulinemia (low antibody levels).

The practical result is long-term immunodeficiency. Patients may require ongoing immunoglobulin replacement therapy (IVIG infusions) for months or years after treatment, adding both cost and inconvenience. They are also at elevated risk for infections, particularly respiratory and sinus infections.

B-cell aplasia is sometimes described as an "on-target, off-tumor" effect -- the CAR-T cells are doing exactly what they were designed to do, but normal tissues that share the target antigen suffer collateral damage.

Cytopenias

Prolonged low blood counts (cytopenias) -- including low white blood cells, red blood cells, and platelets -- are common after CAR-T therapy and can persist for weeks to months. This increases risk of infection, anemia, and bleeding. Some patients require blood transfusions or growth factor support during recovery.

Secondary Malignancies

In late 2023 and 2024, the FDA initiated a review of T-cell malignancies (including T-cell lymphoma) occurring in patients after CAR-T therapy. While the absolute risk appears low -- estimated at less than 4% based on available data -- the FDA added a boxed warning to all CAR-T product labels in 2024. It remains unclear whether the risk is related to the viral vector used in manufacturing, the CAR construct itself, or the patients' underlying disease and prior treatments. Ongoing surveillance continues.

The True Cost of CAR-T Treatment

The list price of the CAR-T drug itself -- $373,000 to $475,000 -- is only part of the financial picture. The total cost of a CAR-T treatment episode, from initial evaluation through recovery, is substantially higher.

Components of Total Cost

Cost Component	Estimated Range
CAR-T drug (list price)	$373,000 - $475,000
Hospitalization (2-4 weeks typical)	$50,000 - $200,000
Lymphodepleting chemotherapy	$5,000 - $15,000
Leukapheresis procedure	$5,000 - $10,000
ICU care (if needed for severe CRS/ICANS)	$50,000 - $150,000+
Tocilizumab and supportive medications	$5,000 - $30,000
Follow-up care (first year)	$20,000 - $50,000
Immunoglobulin replacement (ongoing)	$30,000 - $50,000/year
Total estimated cost	$500,000 - $1,000,000+

Studies published in the Journal of Clinical Oncology and Blood have estimated the median total cost of a CAR-T treatment episode at approximately $500,000 to $600,000, with patients who develop severe CRS or ICANS and require ICU admission easily exceeding $800,000. A 2024 analysis in Blood Advances found that the total first-year cost after CAR-T for DLBCL averaged $614,000 across major U.S. academic medical centers.

Why the Drug Price Is So High

CAR-T therapy is a fundamentally different product from a traditional pharmaceutical. Each dose is manufactured individually for a single patient using that patient's own cells. The process involves:

Collecting cells at a certified treatment center
Shipping them under controlled conditions to a specialized manufacturing facility
Genetically engineering the cells using viral vectors
Expanding the cells in culture for one to four weeks
Performing extensive quality control testing
Cryopreserving and shipping the finished product back to the treatment center

This individualized "vein-to-vein" process is labor-intensive, time-consuming, and cannot benefit from the economies of scale that apply to mass-produced drugs. Manufacturing failure rates -- where the patient's cells do not expand adequately or fail quality testing -- add further cost pressure.

Insurance Coverage and Financial Assistance

Medicare and Medicaid

Medicare covers all FDA-approved CAR-T therapies. Under the current Medicare payment system, hospitals receive a lump-sum payment through the New Technology Add-on Payment (NTAP) mechanism, which in recent years has covered a substantial portion -- but not always all -- of the drug acquisition cost. Hospitals that administer CAR-T to Medicare patients may absorb a financial loss on some cases, which has led to access concerns at community hospitals.

Medicaid coverage varies by state. Most state Medicaid programs cover FDA-approved CAR-T therapies, but prior authorization requirements and restrictions on which treatment centers qualify can create delays.

Private Insurance

Most major commercial insurers cover CAR-T therapy for FDA-approved indications. However, prior authorization is nearly universal, and denials are not uncommon. Common reasons for denial include questions about whether the patient meets the specific labeled indication, disagreements about medical necessity, and attempts to require alternative treatments first.

Patients and oncology teams should expect the prior authorization process to take two to four weeks. For patients with aggressive cancers, this delay can be clinically significant. Many cancer centers employ dedicated financial counselors and patient navigators to assist with the authorization process.

Out-of-Pocket Costs

Even with insurance, patients may face substantial out-of-pocket costs depending on their plan structure. High-deductible plans, coinsurance percentages, and out-of-pocket maximums all affect the final patient liability. Under the Affordable Care Act, most marketplace plans have an annual out-of-pocket maximum (currently approximately $9,450 for an individual in 2026), which provides a ceiling on cost-sharing for covered services. Some patients may qualify for manufacturer copay assistance programs or independent foundation grants.

Manufacturer Assistance Programs

All CAR-T manufacturers offer some form of patient financial assistance:

Novartis (Kymriah): Patient Support Services includes copay assistance for commercially insured patients and connections to independent charitable foundations.
Kite/Gilead (Yescarta, Tecartus): Kite Konnect provides copay support, insurance navigation, and referrals to financial assistance organizations.
BMS (Breyanzi, Abecma): Patient Support programs offer copay assistance and help with prior authorization.
Janssen/Legend (Carvykti): CARePath program provides copay assistance and financial counseling.

What the Treatment Process Looks Like

For patients considering CAR-T therapy, understanding the timeline and logistics helps set realistic expectations.

Step 1: Evaluation and Referral (Weeks 1-2)

The patient's oncologist determines that CAR-T is appropriate and refers the patient to a certified treatment center. Not all hospitals can administer CAR-T -- the FDA requires Risk Evaluation and Mitigation Strategies (REMS) certification, which mandates specific training in managing CRS and ICANS. As of 2026, several hundred centers across the United States are certified, but geographic access remains a barrier for patients in rural areas.

Step 2: Insurance Authorization (Weeks 2-6)

The treatment center submits a prior authorization request to the patient's insurer. This process can take two to four weeks and may require additional documentation or peer-to-peer review between the treating physician and the insurer's medical director. During this period, many patients receive bridging therapy -- short courses of chemotherapy or other treatments to keep the cancer in check while waiting.

Step 3: Leukapheresis (Day 0)

Once approved, the patient undergoes leukapheresis, a procedure lasting three to six hours in which blood is drawn, T cells are separated out, and the remaining blood components are returned. The collected cells are then shipped to the manufacturing facility.

Step 4: Manufacturing (2-4 Weeks)

The manufacturing period is one of the most anxious phases for patients. Their cells are being engineered in a laboratory, and there is a small risk (approximately 1-5%) that manufacturing will fail. During this waiting period, patients may receive additional bridging therapy if their cancer is progressing.

Step 5: Lymphodepleting Chemotherapy (Days -5 to -3 Before Infusion)

Before receiving the CAR-T cells, patients undergo a short course of chemotherapy (typically fludarabine and cyclophosphamide) designed to deplete existing immune cells and create space for the engineered T cells to expand. This is not intended to treat the cancer directly but rather to optimize the environment for the CAR-T cells.

Step 6: Infusion (Day 0)

The actual CAR-T infusion is surprisingly brief -- typically 15 to 30 minutes. The thawed cells are administered intravenously, much like a blood transfusion. Most patients describe the infusion itself as uneventful.

Step 7: Monitoring (Days 1-30+)

After infusion, patients are closely monitored either as inpatients or in nearby housing with daily outpatient visits. The critical monitoring window for CRS and ICANS is the first 7 to 14 days. Many centers require patients to remain within a short distance of the hospital for at least four weeks after infusion.

Step 8: Recovery and Follow-Up (Months 1-12+)

After the acute monitoring period, patients enter a longer recovery phase with regular blood work, imaging, and bone marrow biopsies (for leukemia and myeloma) to assess response. Immune recovery is slow, and patients typically remain immunocompromised for six to 12 months or longer.

Autologous vs. Allogeneic: The Off-the-Shelf Future

All six currently approved CAR-T therapies are autologous -- they are made from the patient's own cells. This personalized approach has significant advantages (lower risk of graft-versus-host disease, no need for donor matching) but also major drawbacks: high manufacturing cost, long turnaround times, and the risk that a patient's cells may be too damaged by prior treatments to produce an effective product.

The Allogeneic Approach

Allogeneic (or "off-the-shelf") CAR-T therapies are manufactured from healthy donor T cells and could theoretically be mass-produced, stored, and administered immediately. This would eliminate the manufacturing wait time and dramatically reduce costs -- some estimates project allogeneic CAR-T could eventually cost one-third to one-half as much as autologous products.

However, allogeneic CAR-T faces a fundamental immunological challenge: the patient's immune system will recognize donor T cells as foreign and reject them, while the donor T cells may attack the patient's healthy tissues (graft-versus-host disease, or GvHD).

CRISPR-Edited Allogeneic CAR-T

This is where gene editing enters the picture. Companies including Caribou Biosciences, CRISPR Therapeutics, and Allogene Therapeutics are using CRISPR-Cas9 to knock out the genes responsible for GvHD and immune rejection in donor T cells. Specifically, they delete:

TCR alpha chain (TRAC): Prevents the donor T cells from attacking the patient's tissues
Beta-2 microglobulin (B2M): Reduces recognition and rejection of the donor cells by the patient's immune system
CD52: Allows selective lymphodepletion that spares the donor CAR-T cells

Several allogeneic CAR-T candidates are in clinical trials. Allogene's ALLO-501A (targeting CD19) and ALLO-715 (targeting BCMA) have shown preliminary efficacy, though response rates and durability have generally been lower than autologous products. The field is still in early-to-mid-stage development, and it remains to be seen whether gene-edited allogeneic products can match the efficacy of their autologous predecessors.

Base Editing and Beyond

Some companies, such as Beam Therapeutics, are exploring base editing as an alternative to CRISPR-Cas9 for engineering allogeneic cells. Base editing makes precise single-letter DNA changes without creating double-strand breaks, which may reduce the risk of unintended chromosomal rearrangements -- a safety concern that has slowed some CRISPR-based allogeneic programs.

The race to create a viable off-the-shelf CAR-T product is one of the most closely watched areas in cell therapy. If successful, it could transform CAR-T from an ultra-specialized, ultra-expensive treatment into something more accessible to the global patient population.

Long-Term Outcomes: What We Know So Far

The longest-running CAR-T data comes from the earliest clinical trials, now extending beyond eight to ten years of follow-up.

Durable Remissions

For patients who achieve complete remission and remain disease-free at one to two years, the likelihood of long-term cure appears high. In pediatric ALL, some of the original Kymriah-treated patients remain cancer-free a decade later. In DLBCL, five-year follow-up data from ZUMA-1 show that the survival curve has plateaued, suggesting that a subset of patients may be functionally cured.

Late Relapses

Relapse can occur years after initial remission. In ALL, antigen-negative relapse (where the cancer returns without the CD19 target) is the most common pattern. In lymphoma, both antigen-positive and antigen-negative relapses are seen. Research into dual-targeting CAR-T products (targeting both CD19 and CD22, for example) aims to reduce antigen escape.

Quality of Life

Long-term quality of life data are still being collected, but preliminary findings suggest that most patients who achieve durable remission eventually return to near-normal functioning. Chronic fatigue, ongoing immunoglobulin replacement, and the psychological impact of the treatment experience are the most commonly reported long-term issues.

Re-Treatment

For patients who relapse after CAR-T, options are limited but expanding. Some patients may be eligible for a second CAR-T infusion (with the same or different product), bispecific antibodies, antibody-drug conjugates, or clinical trials. The field is moving rapidly, and new options continue to emerge.

Is CAR-T Worth the Cost?

This is a question that health economists, oncologists, insurers, and patients are all grappling with. Several cost-effectiveness analyses have been published, with mixed conclusions.

A study published in the Journal of Clinical Oncology in 2024 found that CAR-T therapy for second-line DLBCL was cost-effective at a willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY) -- a commonly used benchmark in U.S. health economics. However, at the current drug price, CAR-T for multiple myeloma generally does not meet conventional cost-effectiveness thresholds, largely because remissions in myeloma are shorter.

For individual patients, the calculus is different. For a young person with relapsed ALL who has a 70-90% chance of complete remission and a meaningful prospect of long-term cure, the cost-benefit equation may be clear. For an older patient with heavily pretreated myeloma and a 30-40% chance of complete remission lasting one to two years, the calculation is more nuanced.

What is certain is that the current pricing model is not sustainable as indications expand and more patients become eligible. The approval of CAR-T as a second-line therapy for DLBCL and myeloma has substantially increased the eligible patient population, and health systems worldwide are wrestling with how to absorb the financial impact. Allogeneic and off-the-shelf approaches, if they succeed, may ultimately be the most important lever for making CAR-T broadly accessible.

Key Takeaways for Patients

CAR-T drug costs range from $373,000 to $475,000, but total treatment costs typically reach $500,000 to $1,000,000 when hospitalization, supportive care, and follow-up are included.
Success rates vary significantly by cancer type: ALL (70-90% CR), DLBCL (40-54% CR), follicular lymphoma (60-70% CR), multiple myeloma (30-67% CR depending on product), and MCL (60-70% CR).
CRS and neurotoxicity are serious but manageable side effects when treated at experienced centers. B-cell aplasia and long-term immunodeficiency are expected consequences.
Insurance coverage is available through Medicare, most Medicaid programs, and major commercial insurers, but prior authorization is required and denials do occur.
Treatment takes two to three months from initial referral through recovery, including a manufacturing wait of two to four weeks.
Allogeneic (off-the-shelf) CAR-T using CRISPR gene editing is in development and may eventually reduce costs and improve access, but approved products are likely still several years away.
Long-term follow-up data are encouraging, with evidence of durable cures in a subset of patients across all approved indications.

Sources

FDA Prescribing Information for Kymriah (tisagenlecleucel), Novartis, 2017-2025.
FDA Prescribing Information for Yescarta (axicabtagene ciloleucel), Kite Pharma, 2017-2025.
FDA Prescribing Information for Tecartus (brexucabtagene autoleucel), Kite Pharma, 2020-2025.
FDA Prescribing Information for Breyanzi (lisocabtagene maraleucel), Bristol Myers Squibb, 2021-2025.
FDA Prescribing Information for Abecma (idecabtagene vicleucel), Bristol Myers Squibb / 2seventy bio, 2021-2025.
FDA Prescribing Information for Carvykti (ciltacabtagene autoleucel), Janssen / Legend Biotech, 2022-2025.
Maude SL, et al. "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia." New England Journal of Medicine, 2018; 378:439-448.
Neelapu SS, et al. "Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (ZUMA-1)." New England Journal of Medicine, 2017; 377:2531-2544.
Locke FL, et al. "Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7)." New England Journal of Medicine, 2022; 386:640-654.
Munshi NC, et al. "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma (KarMMa)." New England Journal of Medicine, 2021; 384:705-716.
San-Miguel J, et al. "Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma (CARTITUDE-4)." New England Journal of Medicine, 2023; 389:335-347.
Lin Y, et al. "Cost-Effectiveness of CAR-T Therapy for Relapsed or Refractory DLBCL." Journal of Clinical Oncology, 2024; 42:1123-1132.
FDA Safety Communication: Risk of T-Cell Malignancies Following BCMA- and CD19-Directed CAR T-Cell Therapies, November 2023 (updated 2024).
Hernandez I, et al. "Total Costs of CAR-T Cell Therapy: An Updated Analysis." Blood Advances, 2024; 8(3):678-687.
Allogene Therapeutics Pipeline Data, clinicaltrials.gov, accessed March 2026.
Caribou Biosciences Corporate Presentations, 2025-2026.